PT967214E - Formulacoes intranasais para o tratamento de desordens sexuais - Google Patents

Formulacoes intranasais para o tratamento de desordens sexuais

Info

Publication number
PT967214E
PT967214E PT99304425T PT99304425T PT967214E PT 967214 E PT967214 E PT 967214E PT 99304425 T PT99304425 T PT 99304425T PT 99304425 T PT99304425 T PT 99304425T PT 967214 E PT967214 E PT 967214E
Authority
PT
Portugal
Prior art keywords
treatment
sexual disorders
intranasal formulations
intranasal
formulations
Prior art date
Application number
PT99304425T
Other languages
English (en)
Inventor
Peter James Dunn
Anne Billotte
Brian Thomas Henry
Peter Vallance Marshall
Joanna Jayne Woods
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of PT967214E publication Critical patent/PT967214E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99304425T 1998-06-22 1999-06-08 Formulacoes intranasais para o tratamento de desordens sexuais PT967214E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
PT967214E true PT967214E (pt) 2004-08-31

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99304425T PT967214E (pt) 1998-06-22 1999-06-08 Formulacoes intranasais para o tratamento de desordens sexuais

Country Status (40)

Country Link
US (2) US20020040139A1 (pt)
EP (1) EP0967214B1 (pt)
JP (1) JP3263379B2 (pt)
KR (1) KR100345824B1 (pt)
AP (1) AP1178A (pt)
AR (1) AR016993A1 (pt)
AT (1) ATE269866T1 (pt)
AU (1) AU746865B2 (pt)
BG (1) BG64372B1 (pt)
BR (1) BR9903273A (pt)
CA (1) CA2275554C (pt)
CZ (1) CZ294856B6 (pt)
DE (1) DE69918222T2 (pt)
DK (1) DK0967214T3 (pt)
DZ (1) DZ2826A1 (pt)
EA (1) EA001903B1 (pt)
ES (1) ES2221733T3 (pt)
GT (1) GT199900095A (pt)
HN (1) HN1999000096A (pt)
HR (1) HRP990195B1 (pt)
HU (1) HUP9902076A3 (pt)
ID (1) ID23554A (pt)
IL (1) IL130539A0 (pt)
IS (1) IS5085A (pt)
MA (1) MA25089A1 (pt)
MY (1) MY117967A (pt)
NO (1) NO317365B1 (pt)
NZ (1) NZ336382A (pt)
OA (1) OA11069A (pt)
PA (1) PA8476301A1 (pt)
PE (1) PE20000702A1 (pt)
PT (1) PT967214E (pt)
SG (1) SG77246A1 (pt)
SI (1) SI0967214T1 (pt)
SK (1) SK284574B6 (pt)
TN (1) TNSN99129A1 (pt)
TR (1) TR199901444A2 (pt)
TW (1) TWI223598B (pt)
UA (1) UA59385C2 (pt)
YU (1) YU29699A (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
AU3048501A (en) * 1999-11-18 2001-05-30 Natco Pharma Limited An improved pharmaceutical composition for treating male erectile dysfunction
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
AU2002310086B2 (en) * 2001-05-24 2008-09-04 Alexza Pharmaceuticals, Inc. Delivery of erectile dysfunction drugs through an inhalation route
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
WO2006042701A1 (de) 2004-10-18 2006-04-27 Polymun Scientific Immunbiologische Forschung Gmbh Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
WO2006094924A2 (en) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and pde 5-inhibitors
MX2007012711A (es) 2005-04-19 2008-01-11 Nycomed Gmbh Roflumilast para el tratamiento de hipertension pulmonar.
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070098804A1 (en) * 2005-08-29 2007-05-03 Judith Aronhime Solid particulate tadalafil having a bimodal particle size distribution
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102008004893A1 (de) 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
US20110033506A1 (en) * 2008-02-08 2011-02-10 Adel Penhasi Combination dosage form of low-dose modafinil and low-dose sildenafil
AU2009228093B2 (en) * 2008-03-28 2014-08-07 Neurelis, Inc. Administration of benzodiazepine compositions
US8747005B2 (en) 2008-06-04 2014-06-10 Colgate-Palmolive Company Oral care implement with cavitation system
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
CN103002882B (zh) 2010-05-10 2016-03-02 欧洲凯尔特公司 不含活性剂之颗粒及包含其之片剂的制备
US9901540B2 (en) 2010-05-10 2018-02-27 Euro-Celtique S.A. Combination of active loaded granules with additional actives
ES2683902T3 (es) 2011-06-14 2018-09-28 Hale Biopharma Ventures, Llc Administración de benzodiacepina
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (en) * 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CA2795324C (en) * 2012-11-09 2015-07-14 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
US20160030435A1 (en) * 2013-03-15 2016-02-04 Robert I HENKIN Phosphodiesterase inhibitor treatment
KR102194174B1 (ko) 2013-11-13 2020-12-23 유로-셀티큐 에스.에이. 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
NO2723977T3 (pt) 2014-03-19 2018-03-10
CA2994709A1 (en) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Sexual dysfunction therapeutic gel
CN109996547A (zh) * 2016-10-31 2019-07-09 苏达有限公司 粘膜活性剂递送
IL269069B (en) 2017-03-02 2022-09-01 Dutch Renewable Energy B V Intranasal administration of physiologically active substances
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CA3086881A1 (en) 2017-12-26 2019-07-04 Ftf Pharma Private Limited Liquid oral formulations for pde v inhibitors
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
US20210161986A1 (en) * 2018-04-16 2021-06-03 Barista Mist Pty Ltd Caffeine compositions and methods of use
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
WO2022026762A1 (en) * 2020-07-29 2022-02-03 Lido Ventures Llc Apparatus, system, and method for facilitating intranasal treatment of a patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69600784T2 (de) * 1995-11-20 1999-04-08 Lilly Co Eli Proteinkinase-C-Inhibitor
WO1998053819A1 (fr) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Agent therapeutique destine a traiter l'anerection
DE69831421T2 (de) * 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
BG103510A (en) 2000-01-31
SK284574B6 (sk) 2005-06-02
HN1999000096A (es) 2000-12-03
BR9903273A (pt) 2000-05-09
PE20000702A1 (es) 2000-08-16
SI0967214T1 (en) 2004-10-31
UA59385C2 (uk) 2003-09-15
CA2275554C (en) 2003-06-03
TNSN99129A1 (fr) 2005-11-10
NZ336382A (en) 1999-11-29
DK0967214T3 (da) 2004-09-27
US20030158206A1 (en) 2003-08-21
NO993051L (no) 1999-12-23
ATE269866T1 (de) 2004-07-15
SK81999A3 (en) 2001-01-18
SG77246A1 (en) 2000-12-19
YU29699A (sh) 2003-02-28
TWI223598B (en) 2004-11-11
PA8476301A1 (es) 2000-09-29
AP1178A (en) 2003-06-30
CA2275554A1 (en) 1999-12-22
HRP990195A2 (en) 2000-02-29
GT199900095A (es) 2000-12-13
AU746865B2 (en) 2002-05-02
MA25089A1 (fr) 2000-12-31
ID23554A (id) 2000-05-04
OA11069A (en) 2002-03-13
CZ294856B6 (cs) 2005-03-16
JP2000034232A (ja) 2000-02-02
EP0967214B1 (en) 2004-06-23
CZ9902257A3 (cs) 2000-11-15
EA199900487A3 (ru) 2000-04-24
HUP9902076A2 (hu) 2000-05-28
HRP990195B1 (en) 2003-04-30
EA199900487A2 (ru) 1999-12-29
TR199901444A2 (xx) 2000-01-21
MY117967A (en) 2004-08-30
AP9901585A0 (en) 1999-06-30
NO317365B1 (no) 2004-10-18
KR100345824B1 (ko) 2002-07-24
DE69918222D1 (de) 2004-07-29
HU9902076D0 (en) 1999-08-30
KR20000006310A (ko) 2000-01-25
BG64372B1 (bg) 2004-12-30
NO993051D0 (no) 1999-06-21
AU3579499A (en) 2000-01-06
IS5085A (is) 1999-12-23
DZ2826A1 (fr) 2003-12-01
US20020040139A1 (en) 2002-04-04
HUP9902076A3 (en) 2002-03-28
JP3263379B2 (ja) 2002-03-04
EP0967214A1 (en) 1999-12-29
DE69918222T2 (de) 2005-07-28
ES2221733T3 (es) 2005-01-01
IL130539A0 (en) 2000-06-01
EA001903B1 (ru) 2001-10-22
AR016993A1 (es) 2001-08-01

Similar Documents

Publication Publication Date Title
PT967214E (pt) Formulacoes intranasais para o tratamento de desordens sexuais
PT1223927E (pt) Utilizacao de retigabina para o tratamento de dores neuropaticas
PT1073658E (pt) Inibidores de ogmp pdes de pirazolopirimidinona para o tratamento da disfuncao sexual
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
GB0007193D0 (en) Treatment of movrmrnt disorders
ID30276A (id) Metode untuk mengobati gangguan-gangguan seksual
ZA200401004B (en) Combination for the treatment of inflammatory disorders
PL351134A1 (en) Compositions for treatment of disorders of the oesophagus
NO20026263L (no) Sulfonyl-pyrrolidin-derivater anvendelige for behandling av neurologiske forstyrrelser
PT1206436E (pt) Retinoides para o tratamento de enfisema
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
BR9712030A (pt) Uso de benzopiranÄis para o tratamento de desordens neurolÄgicas
PT1268482E (pt) Piranoindois para o tratamento de glaucoma
PT1294710E (pt) Derivados de indole uteis para o tratamento de disturbios do snc
PT1051172E (pt) Metodo para tratamento da dpco
HUP0102886A3 (en) Treatment of anxiety disorders
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
ZA994077B (en) Intranasal formulations for treating sexual disorders.
GB9816352D0 (en) The treatment of inflammatory disorders
GB9816349D0 (en) The treatment of inflammatory disorders
NO20041396L (no) Fremgangsmåte for behandling av hudlidelser
GB0003228D0 (en) Treatment of GI disorders
GB0017951D0 (en) Treatment of movement disorders